BACKGROUND INFORMATION ON THE PROCEDURE 
1.1  Submission of the dossier 
The  applicant  Celgene  Europe  Ltd.  submitted  on  28  February  2006  an  application  for  Marketing 
Authorisation  to  the  European  Medicines  Agency  (EMEA)  through  the  centralised  procedure  for 
Revlimid, which was designated as an orphan medicinal product EU/3/03/177 on 12 December 2003. 
Revlimid  was  designated  as  an  orphan  medicinal  product  in  the  following  indication:  treatment  of 
multiple myeloma. 
legal  basis  for 
The 
this  application  refers 
amended - complete and independent application. 
to:  Article  8.3  of  Directive  2001/83/EC,  as 
The  applicant  applied  for  the  following  indication:  Revlimid  in  combination  with  dexamethasone  is 
indicated for the treatment of multiple myeloma patients who have received at least one prior therapy. 
Scientific Advice 
The  applicant  received  Protocol  Assistance  from  the  CHMP  on  19 November 2004.  The  Protocol 
Assistance pertained to non-clinical and clinical aspects of the dossier. 
Licensing status 
Revlimid  has  been  given  first  a  Marketing  Authorisation  in  United  States  of  America    for  the 
myelodysplastic  syndrome  indication  on  27  December  2005  and  then,  for  the  multiple  myeloma 
indication on 29 June 2006. 
A  new  application  for  the  multiple  myeloma  indication  was  filed  in  the  following  countries: 
Switzerland and Australia  
The Rapporteur and Co-Rapporteur appointed by the CHMP were: 
Rapporteur: 
Co-rapporteur: 
Eric Abadie 
Tomas Salmonson 
1.2  Steps taken for the assessment of the product 
•  The application was received by the EMEA on 28 February 2006. 
•  The procedure started on 29 March 2006. 
•  The Rapporteur's first Assessment Report was circulated to all CHMP members on 16 June 2006. 
The  Co-Rapporteur's  first  Assessment  Report  was  circulated  to  all  CHMP  members  on 
16 June 2006. 
•  On 6 July 2006 the following meetings took place at the EMEA: 
•  an  ad  hoc  Pharmacovigilance  Expert  group  meeting  to  give  input  on  pharmacovigilance 
measures and Risk Management Plan 
•  a consultation meeting of Patients’ and Victims’ organisations (representing their organisations, 
based on the agreement from the Applicant to disclose relevant confidential data) to comment 
on the Risk Management Plan, the package leaflet and the labelling: 
•  During the meeting on 25-27 July 2006, the CHMP agreed on the consolidated List of Questions to 
be sent to the applicant. The final consolidated List of Questions was sent to the applicant on. 
•  A  clarification  meeting  with  the  Rapporteurs  on  the  CHMP  List  of  Questions  was  held  at  the 
EMEA on 21 September 2006. 
•  The  applicant  submitted  the  responses  to  the  CHMP  consolidated  List  of  Questions  on 
17 November 2006. 
•  On  12 December 2006,  a  second  ad  hoc  Pharmacovigilance  Expert  group  meeting  on  revised 
pharmacovigilance measures and Risk Management Plan took place at the EMEA. 
•  The Rapporteurs circulated the Joint Assessment Report on the applicant’s responses to the List of 
Questions to all CHMP members on 19 December 2006. 
©EMEA 2007 
1/2 
 
 
 
 
 
 
 
 
 
 
 
 
•  During  the  CHMP  meeting  on  22-24  January  2007,  the  CHMP  agreed  on  a  list  of  outstanding 
issues to be addressed in writing by the applicant. 
•  On  29 January 2007,  the  second  consultation  of  Patients’  and  Victims’  organisations  was  held  to 
comment on the revised Risk Management Plan, the package leaflet and the labelling. Following 
the meeting the list of outstanding issues was amended and adopted via a CHMP written procedure 
in 22 February 2007. 
•  The  applicant  submitted  the  responses  to  the  CHMP  revised  list  of  outstanding  issues  on 
26 February 2007. 
•  During the meeting on 20-22 March 2007, the CHMP, in the light of the overall data submitted and 
the scientific discussion within the Committee, issued a positive opinion for granting a Marketing 
Authorisation to Revlimid on 22 March 2007. The applicant provided the letter of undertaking on 
the follow-up measures to be fulfilled post-authorisation on 22 March 2007. 
•  The  CHMP  opinions  were  forwarded,  in  all  official  languages  of  the  European  Union,  to  the 
European Commission, which adopted the corresponding Decisions on 14 June 2007. 
©EMEA 2007 
2/2 
 
